Status: Not yet recruiting
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke
This study is a prospective, multicenter, double-blind, randomized, placebo-controlled clinical trial designed to evaluate whether early administration of PCSK9 inhibitors can effectively improve functional outcomes at 90 days in patients with ischemic stroke (AIS) associated with intracranial atherosclerotic stenosis (ICAS), primarily assessed using the modified Rankin Scale at 90 days.
Participants needed: 1,212
Trial details
Phase: Phase 4Age: 30-80Biological sex: AllType: InterventionalSponsor: Peking Union Medical College HospitalUpdated: Mar 12, 2026Locations: 19
Eligibility criteria
Age >=30 and <=80;2.Acute ischemic stroke within 72 hours of onset (as determine... [+4]
Non-atherosclerotic intracranial arterial stenosis (such as arterial dissection,... [+12]